חוב לטווח קצר להון עצמי UroGen Pharma Ltd (URGN)

UroGen Pharma Ltd. (URGN) develops innovative methods for combating oncology. This price chart illustrates the asset's dynamics, where the individual debt-to-equity ratio stands at 0.00. The business relies on a unique therapeutic gel that has created a monopoly in urology, despite the risks of government price regulation. Meanwhile, drug production is fully delegated to external contractors through strict agreements.

Fundamental asset selection requires solvency analysis via the ratio of short-term liabilities to equity to eliminate devaluation risks. The current value of 0.00 reflects the share of loans under one year within the capital structure of UroGen Pharma Ltd. (URGN), which is critical when financing marketing for gel sales; therefore, the short-term debt-to-equity trend confirms the stability of the issuer's financial cushion.